API | abetimus

abetimus (Riquent) Report issue

Small molecule Experimental

AACT ChEMBL MeSH

Active Ingredient History

NOW

Abetimus is an immunosuppressant. It is a synthetic biological called a tolerogen. It is made of four double-stranded oligodeoxyribonucleotides that are attached to a carrier platform and are designed to block specific B-cell anti double stranded DNA antibodies. It may also complex anti dsDNA antibodies together, therefore disabling them. This way abetimus was supposed to help treat systemic lupus erythematosus and specifically lupus nephritis. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules:

abetimus

abetimus sodium

More Chemistry

Pharmacology

Mechanisms of Action:
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

abetimus | abetimus sodium | ljp 394 | ljp-394

Organizations (1)

Research & Development (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (4)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (4)

Autoimmune Diseases (Phase 3)

Immune System Diseases (Phase 3)

Lupus Erythematosus, Systemic (Phase 3)

Lupus Nephritis (Phase 3)

Overview

Highest Phase: Phase 3
# of Trials: 3
# of Trial Organizations: 1

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue